Inovio Pharmaceuticals, Inc. (NASDAQ:INO)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Friday. They presently have a $13.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 111.38% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. Maxim Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of Inovio Pharmaceuticals in a research note on Thursday, June 1st. Aegis increased their target price on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, May 25th. Stifel Nicolaus reiterated a “buy” rating and set a $11.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, May 25th. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a research report on Tuesday, July 11th. Finally, Citigroup Inc. began coverage on Inovio Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $10.00 target price on the stock. Two research analysts have rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.80.

Inovio Pharmaceuticals (NASDAQ INO) opened at 6.15 on Friday. Inovio Pharmaceuticals has a one year low of $5.28 and a one year high of $9.86. The firm’s 50-day moving average is $5.73 and its 200 day moving average is $6.65. The stock’s market cap is $554.90 million.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $20.41 million for the quarter, compared to analysts’ expectations of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The business’s revenue was up 229.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.26) EPS. On average, analysts anticipate that Inovio Pharmaceuticals will post ($0.92) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/24/hc-wainwright-reiterates-buy-rating-for-inovio-pharmaceuticals-inc-ino.html.

A number of hedge funds have recently made changes to their positions in INO. BlueCrest Capital Management Ltd purchased a new position in Inovio Pharmaceuticals in the 2nd quarter valued at $107,000. PNC Financial Services Group Inc. lifted its holdings in Inovio Pharmaceuticals by 5.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Inovio Pharmaceuticals in the 2nd quarter valued at $171,000. Bank of America Corp DE lifted its holdings in Inovio Pharmaceuticals by 14.6% in the 1st quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 3,605 shares in the last quarter. Finally, OxFORD Asset Management LLP purchased a new position in Inovio Pharmaceuticals in the 2nd quarter valued at $194,000. Institutional investors own 24.83% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.